Congress enlists GAO in drug shortages probe

Another U.S. congressman has boarded the drug-supply bandwagon. Sen. Richard Blumenthal of Connecticut has asked the Government Accountability Office to investigate recent and growing shortages.

His request follows last month's legislation proposal by Sens. Amy Klobuchar of Minnesota and Bob Casey of Pennsylvania that would require drugmakers to give the FDA early notice of supply interruptions.

Blumenthal sees a need for stronger action, according to the Hartford Courant. He wants GAO to determine what causes the shortages and how they affect patient care. His office, meanwhile, will look into pharma's knowledge of impending shortages and its responsibility to maintain adequate supplies. He plans also to investigate the timing of pharma shortage alerts to hospitals.

- read the story
- here's more on the Klobuchar/Casey effort


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.